trial

eMotiph: E-mental Health Solution for Patients With Schizophrenia

NCTId NCT05345977
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Completed
Enrollment 7 (actual)
Sponsored by Grupo Pulso
Primary completion 2022-02-28
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
7 (actual)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2021-06-01
Primary completion
2022-02-28
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
eMotiph

Sponsors

Grupo PulsoLead Sponsor
Hospital de Sant PauCollaborator
Nurogames GmbHCollaborator
Fundació Tic Salut i SocialCollaborator

Investigators

1
Iluminada Corripio, MD, PhDPrincipal Investigator

Sites

1 total
Barcelona, Spain

Facts & assertions

4 sourced
Enrollment
7
Phase
NA
Primary Completion Date
2022-02-28
Status
COMPLETED
relationships
The graph out of here
drug
eMotiph
drug
lead_sponsor
Grupo Pulso
company
collaborator
Hospital de Sant Pau
company
Nurogames GmbH
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Iluminada Corripio, MD, PhD
person